Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Mural Oncology plc

We know that drug development is both an art and a science.

The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us.

Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living.

Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. 

Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies.  

We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective.

Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)


Mural Oncology

Today marks a notable milestone as Mural Oncology officially launches as an independent, publicly traded, clinical-stage immuno-oncology company. Tomorrow, find us on Nasdaq as $MURA.

Mural's dedication to advancing our pipeline of novel engineered cytokine immunotherapies with our lead candidate, nemvaleukin alfa, is backed by a strong foundation of $275 million in committed funding, and a clear vision to reimagine cytokine-based immunotherapies for the treatment of cancer. 

Our mission is simple: to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Learn more:  https://bit.ly/47AUnhN #oncology #biotechnology #innovation #immunooncology #Nasdaq

	Dec '21	Dec '22	Dec '23
revenue
cost of revenue			2.57M -
gross profit			-2.57M -
selling and marketing expenses
general and administrative expenses	15.55M -	25.08M 61.29%
selling general and administrative expenses	15.55M -	25.08M 61.29%	30.04M 19.79%
research and development expenses	159.82M -	170.07M 6.41%	162.03M 4.73%
other expenses
cost and expenses	175.37M -	195.15M 11.28%	194.64M 0.26%
operating expenses	175.37M -	195.15M 11.28%	192.07M 1.58%
interest expense
ebitda	-173.89M -	-193.61M 11.34%	-192.07M 0.79%
operating income	-175.37M -	-195.15M 11.28%	-194.64M 0.26%
depreciation and amortization	1.47M -	1.54M 4.48%	2.57M 66.69%
total other income expenses net			-649K -
income before tax	-175.37M -	-195.15M 11.28%	-195.29M 0.07%
income tax expense	68K -	4.88M 7,082.35%	12.16M 148.98%
net income	-175.43M -	-200.03M 14.02%	-207.45M 3.71%
weighted average shs out	16.69M -	16.69M 0%	16.69M 0.01%
weighted average shs out dil	16.69M -	16.69M 0%	16.69M 0.01%
eps	-10.51 -	-11.99 14.08%	-12.43 3.67%
epsdiluted	-10.51 -	-11.99 14.08%	-12.43 3.67%

MURA

COM:MURALONCOLOGY

Mural Oncology plc

Last Close

3.37

22/11 21:00

Market Cap

51.45M

Beta: -

Volume Today

35.85K

Avg: -

Preview